Premium
mTOR inhibitor‐associated dermatologic and mucosal problems
Author(s) -
Campistol Josep M.,
de Fijter Johan W.,
Flechner Stuart M.,
Langone Anthony,
Morelon Emmanuel,
Stockfleth Eggert
Publication year - 2010
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2010.01232.x
Subject(s) - medicine , discovery and development of mtor inhibitors , sirolimus , adverse effect , pi3k/akt/mtor pathway , dermatology , protein synthesis inhibitor , antibacterial agent , signal transduction , biochemistry , chemistry , microbiology and biotechnology , biology , antibiotics
Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor‐associated dermatologic and mucosal problems.
Clin Transplant 2010 DOI: 10.1111/j.1399‐0012.2010.01232.x.
© 2010 John Wiley & Sons A/S. Abstract: Mammalian target of rapamycin inhibitor use is associated with numerous adverse events, including dermatologic and mucosal problems. Awareness of these complications, which clinically manifest across a severity spectrum from minor through severe and may occur at varied time points after initiation of sirolimus therapy, can be useful to clinicians in both managing these events and determining the appropriate intervention(s) for patients. This manuscript examines the dermatologic and mucosal problems associated with mammalian target of rapamycin inhibitor use, reviews the literature, and provides personal experiences regarding the management and treatment of these adverse events.